Skip to main content
Figure 1 | Diabetology & Metabolic Syndrome

Figure 1

From: Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers

Figure 1

Study protocol. The patients were treated with glimepiride monotherapy for 8 weeks to achieve glycemic control. After changing treatment to repaglinide, the patients were monitored for 12 weeks to ensure they had stable glucose control. Blood and urine samples were collected, and CGM was performed at the end of both treatment periods.

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us